Rinvoq (Upadacitinib) is used to treat adults with active psoriatic arthritis (PsA), active ankylosing spondylitis (AS), moderate to severe ulcerative colitis (UC), and moderate to severe rheumatoid arthritis (RA) when one or more medications called tumor necrosis factor (TNF) blockers have been used without success or could not be tolerated. It is also used to treat adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation when a TNF blocker medication has been used without success or could not be tolerated. Rinvoq is also used to treat adults and children over 12 years old with moderate to severe atopic dermatitis that has not responded to previous treatments including biologic medications. Upadacitinib belongs to a class of medications known as Janus Kinase (JAK) inhibitors. This medication works by suppressing the immune system. It helps to decrease pain, tenderness and swelling in the joints.
The brand Rinvoq tablet comes from Canada manufactured by Abbvie. It is available in the dosage of 15 mg tablets only.
The common side effects of Rinvoq may include cold symptoms, cough, fever and nausea. Call your doctor right away if you have any of the serious side effects such as:
• Loss of appetite;
• Signs of anemia;
• Signs of a serious tear in the stomach;
• Signs of liver disease;
• Stomach or abdominal pain;
• Yellowing eyes, skin or dark urine
This is not a complete list of side effects and others may occur. Please call your doctor if you have any further concerns or questions.
You should not take Rinvoq if you are allergic to Upadacitinib or if you have any other allergies. Before you start taking this medication, talk to your doctor about your medical history and about all the medications you take including OTC and herbal medications. Inform your doctor if you have ever had tuberculosis or if anyone in your household has tuberculosis. It is not known if you Rinvoq is safe and effective in children under 18 years of age. You may need to have a negative pregnancy test before you start this treatment. Upadacitinib may harm an unborn baby. You should use an effective form of birth control to prevent pregnancy while you are using this medication and for at least four weeks after you stop using this medication. Do not breastfeed while using this medication and for at least 6 days after your last dose. There may be a drug interaction between Rinvoq and other medications such as phenytoin, clarithromycin, fluconazole, itraconazole, azathioprine, cyclosporine, aspirin, ibuprofen, prednisone etc.